Obesity Surgery最新文献

Background: Conventional vertical sleeve gastrectomy (cVSG), the most commonly performed bariatric surgery, is associated with low complications, durable weight loss, and significant improvement of many obesity-related comorbidities. However, numerous studies have reported that patients who underwent the cVSG have worsening or new onset (de novo) gastroesophageal reflux disease (GERD) which could be related to a negative effect of the operative procedure on the geometry of the gastroesophageal junction impacting on the function of the native gastroesophageal valve. It is imperative to innovate the cVSG procedure because chronic GERD is a debilitating condition associated with increased risk for Barrett's esophagus and esophageal cancer. INNOVATE-VSG aims to test whether a modified flap valve-preserving VSG (fvpVSG), compared to cVSG, will be associated with improvement of preexisting GERD.

Methods: The fvpVSG incorporates the following surgical modifications that strengthen the antireflux barrier: achieving 3 cm intrabdominal esophageal length; repair of the diaphragmatic crura; and preservation of 3 cm length of gastric fundus/cardia during the sleeve gastrectomy procedure which will be used to symmetrically wrap around the distal esophagus (120-160° wrap) to restore the naturally occurring gastroesophageal valve. A total of 44 obese patients (BMI 35-50 kg/m²) with pathologic GERD, confirmed by abnormal acid exposure time (AET), will be randomly assigned to cVSG or fvpVSG in this pilot randomized clinical trial at two academic sites. The primary outcome is the change in AET at 6-9 months after surgery. Secondary outcomes include changes in the lower esophageal sphincter pressure, compliance of the esophagogastric junction, weight loss, and quality of life.

Discussion: Data generated from the INNOVATE-VSG trial will be used to design a larger multi-center randomized clinical trial to confirm the value of preserving a functioning gastroesophageal valve following sleeve gastrectomy.

Background: Obesity is a relapsing condition and response to anti-obesity therapies appears to be normally distributed. Therefore, some patients undergoing metabolic bariatric surgery (MBS) will demonstrate a partial response to therapy. When prescribing therapies to patients living with obesity (PwO) the median total weight loss (TWL) gives a good indication of the likely utility of prescription for that individual. GLP-1 agonists (GLP1a) offer patients a reasonable prospect of clinically significant weight loss even if they have been previously treated with MBS.

Methods: A retrospective review of prospectively collected data in a single bariatric clinic was performed. Patients with insufficient weight loss at any time point were offered semaglutide therapy with doses titrated depending on response to treatment, tolerability, availability and affordability. Duration of therapy, highest dose tolerated, anthropometric measures and reported side effects were recorded. Reasons for discontinuation were noted where possible; however, discontinuation due to medication unavailability was not reliably captured in the dataset.

Results: The median dose tolerated was 1 mg s/c per week, and 78% tolerated ≤ 1 mg as the maximum achieved dose. The median TWL was 7.5% and side effects were uncommon. Most patients took therapy for > 6 months, but continued therapy > 1 year was uncommon.

Conclusion: Overall 'real-world' utility of semaglutide after MBS may potentially be hampered by supply and cost issues more than issues associated with effectiveness or side effect profile.

Background: The predictive ability of vitamin D for weight loss after bariatric surgery is not well-characterized. This prospective cohort study assessed the utility of preoperative serum 25-hydroxyvitamin D (25(OH)D) as a predictor of body mass index (BMI) at follow-up after bariatric surgery. Additionally, the mediation role of serum albumin was explored.

Methods: Patients scheduled for bariatric surgery were recruited from a single center. The final analyzed cohort consisted of 316 subjects (age, 40 ± 10 years; 35.4% males; BMI, 42.6 ± 7.2 kg/m²). The associations between preoperative 25(OH)D and baseline (pre-surgery) BMI or repeated measures of BMI collected at baseline, and 3-, 6-, and 12-month post-surgery were examined using linear regression or linear mixed model, respectively. The mediation effect of baseline albumin was evaluated using mediation analysis.

Results: Before surgery, 98.5% of patients had vitamin D insufficiency (25(OH)D < 30 μg/L). Baseline BMI elevated progressively as severity of vitamin D insufficiency increased (P-trend = 0.025). Lower 25(OH)D levels were independently associated with higher preoperative BMI (coefficient, - 0.20; 95% CI, - 0.32 to - 0.08; P = 0.001) or less BMI reduction at follow-up (coefficient, - 0.15; 95% CI, - 0.25 to - 0.04; P = 0.007), after adjustment for baseline demographics, diabetes status, and/or surgical procedure. The association diminished after accounting for albumin, which emerged as a significant determinant (coefficient, - 0.61; 95% CI, - 0.83 to - 0.40; P < 0.001). Mediation analysis showed that reduced albumin explained 30% (P < 0.001) of the relationship between 25(OH)D and longitudinal BMI.

Conclusions: Lower preoperative 25(OH)D is associated with less BMI reduction over 1-year follow-up after bariatric surgery, potentially mediated by reduced serum albumin.

Introduction: Metabolic and bariatric surgery (MBS) is a safe and effective treatment option to reduce weight and manage obesity-related medical conditions in patients with obesity. However, due to limited data, there is uncertainty regarding the short-, mid-, and long-term safety and efficacy profile of MBS in patients with a preoperative ASA IV status.

Methods: A single-center retrospective cohort study was performed on patients with ASA IV status who underwent sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), or biliopancreatic diversion with duodenal switch (BPD-DS) between 2008 and 2020. Data collected included operative details; postoperative complications at 30 days, 90 days, and beyond 90 days; BMI changes; and resolution of obesity-related comorbidities at 0, 6, 12, 24, 48, and 60 months postoperatively.

Results: Among 131 ASA class IV patients, 43 patients underwent SG (32.8%), 66 patients underwent RYGB (50.4%), and 22 patients underwent BPD-DS (16.8%). The greatest %TWL occurred in the BPD-DS cohort (39.5%) at 24 months post-op followed by the RYGB (32.5%) and SG (20.7%) cohorts (p < 0.001). The overall major 30-day complication rate was 8.4% (n = 11/131), while the overall major 90-day complication rate within the cohort was 6.9% (n = 9/131). The overall major late (> 90 days) complication rate was found to be 14.5% (n = 19/131).

Conclusions: Our study demonstrated that MBS is relatively safe and effective in ASA IV patients in the short-, mid-, and long-term. Accordingly, careful procedure selection is required in this patient population. Further long-term studies are needed to support our findings.

Background: Polycystic ovary syndrome (PCOS) is a prevalent metabolic and endocrine disorder affecting women of reproductive age, particularly those with obesity. This syndrome is characterized by clinical/biochemical hyperandrogenism and/or ovulatory dysfunction, which can result in infertility.

Purpose: To investigate the prevalence of PCOS in candidates for bariatric surgery and to examine the correlation between PCOS and sex hormones in women with obesity.

Methods: A retrospective study analyzed 577 bariatric surgery candidates from 2015 to 2021 using RStudio. Normally distributed data were expressed as x ± s and compared with ANOVA or T-test, while the Kruskal-Wallis test was used for non-normal data. Count data, presented as M [Q1, Q3], were analyzed with the Chi-square test. Logistic regression identified influencing factors, with P < 0.05 indicating statistical significance.

Results: The findings of our study reveal that the prevalence of PCOS among bariatric surgery candidates stands at 14.04%. Conversely, high-density lipoprotein cholesterol (HDL-C) levels tended to decrease with higher BMI categories (P = 0.02). Compared to the non-PCOS group, the PCOS group exhibits lower age and HDL-C levels. Still, they showed significantly elevated HOMA-IR, fasting blood glucose (FBG), luteinizing hormone (LH), total testosterone (TT), and luteinizing hormone/follicle-stimulating hormone (LH/FSH) ratio (P < 0.05). The logistic regression analysis of PCOS indicates that, compared to the control group, those with FBG levels exceeding 7 mmol/L (OR = 2.28, 95% CI 1.19 to 4.37, P = 0.01) and individuals with TT levels greater than 2.01 ng/ml (OR = 2.36, 95% CI 1.23 to 4.71, P = 0.01) exhibited an increased risk of PCOS.

Conclusion: PCOS is highly prevalent among female bariatric surgery candidates. It is significantly associated with younger age, lower HDL, higher FBG, and elevated TT levels. These factors may also serve as indicators for evaluating PCOS improvement and assessing surgical outcomes postoperatively.

Background: Laparoscopic Roux-En-Y Gastric Bypass (LRYGB) contributes significantly to higher weight loss at 6 to 12 months when compared to Laparoscopic Sleeve Gastrectomy (LSG) in patients with severe obesity (SO-body mass index (BMI) ≥ 50 kg/m²). However, there is still no consensus regarding the best procedure in terms of mortality and complication rates. We performed a systematic review and meta-analysis to compare the complication rates between these two surgical procedures.

Methods: PubMed, EMBASE, and Cochrane Central were searched for studies that compared LRYGB and LSG in SO patients. We pooled outcomes for mortality and complications, defined as bleeding, cardiovascular events, conversion to open procedure, and a composite endpoint of leak, abscess, fistulas, and reoperation. Length of stay and operative time were also pooled. A random-effects model was used, and statistical analyses were performed using R version 4.4.0.

Results: A total of 156,767 patients from 28 observational studies were included, of whom 79,324 (50.6%) underwent LRYGB and 77,443 (49.4%) LSG. Length of stay (MD 0.45; 95% CI 0.42-0.48; P < 0.01) and operative time (MD 58.88; 95% CI 37.88-79.87; P < 0.01) were lower in the LSG group. Overall, there was no difference in mortality (OR 1.28; 95% CI 0.80-2.04; P = 0.311) and in complication rates (OR 1.22; 95% CI 0.85-1.76; P = 0.287). A subgroup analysis showed lower conversion to open procedure for patients who underwent LSG (OR 2.75; 95% CI 1.90-3.98; P < 0.001), and no difference was noted in bleeding (OR 0.98; 95% CI 0.47-2.07; P = 0.965), cardiovascular events (OR 0.99; 95% CI 0.43-2.29; P = 0.983), and a composite endpoint of leak, abscess, and fistulas (OR 0.82; 95% CI 0.67-1.01; P = 0.066).

Conclusion: Our meta-analysis suggests that there is no difference in mortality and complication rates between the two groups. However, length of stay and operative time were lower in SO patients who underwent LSG.

Background: Endoscopic gastric pouch plications (EGPP) have emerged as a novel approach for managing weight-related issues and postoperative complications following bariatric surgery. However, safety for these revisions remains limited. This study aims to evaluate the 30-day rate of serious complications and mortality associated with EGPP using the MBSAQIP database.  METHODS: A retrospective analysis of the MBSAQIP database from 2020 to 2022 was conducted, focusing on patients undergoing EGPP. The primary outcomes were 30-day serious complications and mortality.

Results: The study included 1474 patients. Recurrent weight gain was the most common indication for EGPP (71.9%), followed by suboptimal initial weight loss (15.1%), dumping syndrome (5.5%), reflux (4.1%), gastrointestinal tract fistula (1.0%), and others (0.9%). The mean operative time was 41.2 ± 35.2 min, with a mean hospital stay of 0.4 ± 0.7 days. Postoperative complications included 30-day readmissions (3.1%), serious complications (3.3%), 30-day interventions (2.5%), bleeding (0.8%), and reoperations (0.4%). The mortality rate was 0%. Multivariable analysis identified GERD as an independent predictor of serious complications (OR 1.79, 95% CI 0.98 to 3.2, p = 0.05) when adjusting for various factors.

Conclusions: EGPP is an uncommon procedure with only 1474 cases reported, primarily indicated for weight recurrence. It appears to be a relatively safe alternative to surgical revision. However, further research is needed to assess its efficacy and compare it to corresponding surgical revisions.

Background: Despite the growing body of literature on the effects of bariatric surgery on sleep structure and quality in obese patients, there remains a paucity of comprehensive assessments. The objective of this study was to systematically analyze the changes in sleep structure and quality after bariatric surgery in obese patients.

Methods: By searching the three major databases, PubMed, Embase, and Cochrane, eligible studies that provided indicators of Epworth sleepiness scale (ESS) or Pittsburgh sleep quality index (PSQI) outcomes after bariatric surgery will be included in the final analysis.

Results: A total of 1570 weight loss patients from 31 studies were included, with a mean preoperative age of 30.3-56.8 years and a mean body mass index (BMI) of 31.1-62.0 kg/m². Twenty-six of these studies provided ESS data, and seven provided PSQI data. The results of the meta-analysis showed that compared to the preoperative period, postoperative weight loss Excessive daytime sleepiness (EDS) decreased by - 4.604 (I² = 92.9%, P = 0.000) and sleep quality improved by 3.276 (I² = 19.3%, P = 0.282) compared to preoperative.

Conclusions: Bariatric surgery corrects EDS and significantly improves sleep quality in obese patients.